The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
Abstract
Oestrogen receptor (ERα) expression is a strong predictor of response to endocrine therapy. The PI3K/AKT/mTOR signal transduction pathway has been implicated in endocrine resistance in vitro. The present study was carried out to test the hypothesis that AKT activation mediates tamoxifen resistance in clinical breast cancer. Immunohistochemistry (IHC) using AKT1‐3, pan‐AKT, pAKT (Thr‐308), pAKT (Ser‐473), pER (Ser‐167), and pHER2 antibodies was performed on 402 ERα‐positive breast carcinomas from patients treated with tamoxifen. High pAKT (Ser‐473) activity (p = 0.0406) and low AKT2 expression (p = 0.0115) alone, or in combination [high pAKT (Ser‐473)/low AKT2; ‘high‐risk’ patient group] (p = 0.0014), predicted decreased overall survival in tamoxifen‐treated patients with ERα‐positive breast cancers. There was no significant association between tumour levels of AKT expression or activity and disease‐free survival (DFS); however, the ‘high‐risk’ patient group was significantly more likely to relapse (p = 0.0491). During tamoxifen treatment, neither AKT2 nor pAKT predicted DFS. Finally, activation of AKT, via phosphorylation, was linked to activation of both HER2 and ERα in this patient cohort. The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERα‐positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance. Patients with a ‘high‐risk’ expression profile were at increased risk of death (hazard ratio 3.22, p = 0.002) relative to ‘low‐risk’ patients, highlighting the potential that tumour profiling, with multiple IHC markers predictive of therapeutic response, may improve patient selection for endocrine therapies, eg tamoxifen or aromatase inhibitor‐based treatments. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Clark, A. S., West, K. A., Streicher, S. A., & Dennis, P. A. (2002) · PubMed · Cited by 589
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal
Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., & Haga, N. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01345.x · Cited by 502
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production
DOHOON, K., SUNHONG, K., HYONGJONG, K., SANG‐OH, Y., AN‐SIK, C., KYOUNG SANG, C., & JONGKYEONG, C. (2001) · The FASEB Journal · doi:10.1096/fj.01-0198com · Cited by 489
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Self-citationActivation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Mitogenic Activation, Phosphorylation, and Nuclear Translocation of Protein Kinase Bβ
Meier, R., Alessi, D. R., Cron, P., Andjelković, M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30491 · Cited by 378
Sun, M., Paciga, J. E., Feldman, R. I., Yuan, Z., Coppola, D., Lu, Y., Shelley, S. A., Nicosia, S. V., & Cheng, J. Q. (2001) · PubMed · Cited by 360
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343
Schiff, R., Massarweh, S. A., Shou, J., & Osborne, C. K. (2003) · PubMed · Cited by 304
Physiological functions of protein kinase B/Akt
Yang, Z.-Z., Tschopp, O., Baudry, A., Dümmler, B., Hynx, D., & Hemmings, B. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320350 · Cited by 283
Abd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J. A., Rampaul, R. S., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602184 · Cited by 256
Inhibition of protein kinase B/Akt
Hill, M. M., & Hemmings, B. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00193-6 · Cited by 245
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards, J., Krishna, N. S., Witton, C. J., & Bartlett, J. M. S. (2003) · PubMed · Cited by 213
Self-citationVasko, V, Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V, Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015339 · Cited by 211
Thompson, J. E., & Thompson, C. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.103 · Cited by 206
Stoica, G. E., Franke, T. F., Moroni, M., Mueller, S., Morgan, E., Iann, M. C., Winder, A. D., Reiter, R., Wellstein, A., Martin, M. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206769 · Cited by 173
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 165
Park, B. K., Zeng, X., & Glazer, R. I. (2001) · PubMed · Cited by 155
Osborne, C. K., & Schiff, R. (2003) · The Breast · doi:10.1016/s0960-9776(03)00137-1 · Cited by 146
The clinical evaluation of HER‐2 status: which test to use?
Bartlett, J. M. S., Mallon, E., & Cooke, T. (2003) · The Journal of Pathology · doi:10.1002/path.1354 · Cited by 142
Self-citationTovey, S., Dunne, B., Witton, C. J., Forsyth, A., Cooke, T. G., & Bartlett, J. M. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0196 · Cited by 141
Self-citationJohnston, S. R. D., Head, J. E., Pancholi, S., DETRE, S. I., Martin, L., Smith, I. E., & Dowsett, M. (2003) · PubMed · Cited by 138
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Clemons, M. J., Coleman, R., & Verma, S. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.03.004 · Cited by 132
Fleming, F. J., Myers, E. A., Kelly, G., Crotty, T. B., McDermott, E. W. M., O’Higgins, N. J., Hill, A. D. K., & Young, L. S. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.016733 · Cited by 129
Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells
Jordan, N., Gee, J. M. W., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000041623.21338.47 · Cited by 127
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
Hortobágyi, G. N. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90108-3 · Cited by 105
Witton, C. J., Hawe, S. J. K., Cooke, T. G., & Bartlett, J. M. S. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01898.x · Cited by 87
Self-citationGradishar, W. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-378 · Cited by 67
Le, X., Hittelman, W. N., Liu, J., McWatters, A., Li, C., Mills, G. B., & Bast, R. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206175 · Cited by 62
Breast cancer prevention—clinical trials strategies involving aromatase inhibitors
Goss, P. E. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00378-9 · Cited by 54
A perspective on surrogate endpoints in controlled clinical trials
Molenberghs, G., Burzykowski, T., Alonso, A., & Buyse, M. E. (2004) · Statistical Methods in Medical Research · doi:10.1191/0962280204sm362ra · Cited by 53
A role for BRCA1 in sporadic breast cancer
Fraser, J. A., Reeves, J., Stanton, P. D., Black, D. M., Going, J. J., Cooke, T., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600863 · Cited by 50
Self-citationModulation of estrogen receptor activity by selective coregulators
Martini, P. G. V., & Katzenellenbogen, B. S. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00207-3 · Cited by 45
Cited by
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz, N., & Jücker, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0450-3 · Cited by 355
Ageing, oxidative stress and cancer: paradigms in parallax
Benz, C. C., & Yau, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2522 · Cited by 278
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Mesenchymal stem cells and cancer: Friends or enemies?
Hong, I.-S., Lee, H.-Y., & Kang, K.-S. (2014) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2014.01.006 · Cited by 82
Metadata
- Authors
- Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A., & Bartlett, J. M.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2005-08-09
- Volume
- 207
- Issue
- 2
- Pages
- 139-146
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1985453548
- Cited by
- 268
- References
- 56
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
